Mainz Biomed N.V. announced the second phase of its colorectal cancer (CRC) screening campaign through its BGM (betriebliches Gesundheitsmanagement) partnership with Bantleon. Bantleon selected ColoAlert, Mainz Biomed?s highly efficacious and easy-to-use screening test for CRC, for its corporate health program (BGM). This continued BGM initiative follows a successful pilot program and will launch in First Quarter 2024 in line with CRC awareness month March.

Via the Company?s BGM program, Bantleon offers ColoAlert to its employees across all three sites in Germany ? Ulm, Ulm-Nord and Crimmitschau. Bantleon employees are able to register using Mainz Biomed?s online portal and have the ColoAlert test mailed to them.

Once the sample is received and processed, confidential test results are returned to the employee through the portal, along with an explanation of the results. Employees can also approve for their physician to be notified of the test results in which case, their doctor can directly follow-up with them. As part of its commitment to the BGM program, Mainz Biomed provides education to employees and physicians on CRC and recommendations for next steps.